Baxter International Stock - Analyst consensus and sector backdrop on a quiet news day
19.06.2026 - 12:57:44 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 10:56 UTC. Details in the imprint.
Baxter International (US0673431090) draws attention on Friday without a fresh market-moving headline. Instead, the focus is on where the stock sits in analyst consensus and how it compares with other large-cap healthcare suppliers in the current market backdrop.
All news and data on Baxter International stock
Stay on top of Baxter International’s latest filings, earnings releases and price data with our continuously updated topic page.
How analysts view Baxter now
Analyst coverage of Baxter International remains broad, with most large US and European brokerage houses maintaining ratings after the spin-off of the kidney care business Vantive, which closed on 01/31/2024 according to a company announcement and follow-up industry coverage.
Consensus data from major financial portals show a mix of Buy, Hold and a smaller number of Sell ratings, resulting in an overall Neutral to moderately positive stance on the stock. Price targets cluster in a corridor moderately above and below the current share price, reflecting expectations for steady but not explosive earnings growth.
Sector comparison on a Friday
On Friday, Baxter International shares trade in a healthcare equipment and supplies sector that has seen mixed performance in recent weeks, with some diagnostics and medtech names outperforming while hospital-focused suppliers have lagged broader market benchmarks like the Standard & Poor's 500 index.
Against this backdrop, Baxter’s profile as a provider of infusion systems, IV solutions and hospital pharmacy technologies places it alongside peers whose revenues are tied closely to hospital procedure volumes and capital budgets, both of which investors monitor for signs of cyclical softness or recovery.
Recent strategic reshaping and peers
Baxter International Inc. has been reshaping its portfolio, highlighted by the separation of its kidney care unit into Vantive and a sale transaction valued at about $3.8 billion, a process that concluded in early 2024 after a two-year restructuring phase.
This repositioning brings Baxter more squarely into competition with other focused hospital-product and medication delivery specialists, while dialysis and renal-care peers now sit largely under the newly independent Vantive umbrella or rival pure-play kidney care companies.
What the company sells
Baxter International generates the bulk of its revenue from medical products such as infusion pumps, intravenous solutions, parenteral nutrition, anesthesia and critical-care therapies, as well as from related services and technologies that support hospitals, clinics and other care providers worldwide.
Where the stock trades today
The shares of Baxter International (US0673431090) trade on the New York Stock Exchange at around $XXX.XX as of 06/19/2026, 10:30 ET.
Key facts on Baxter International stock
- Company: Baxter International Inc.
- ISIN: US0673431090
- WKN: 855300
- Ticker: BAX
- Venue: NYSE
- Price (as of 06/19/2026, 10:30 ET): XXX.XX USD
- Market cap: [value] USD (as of 06/19/2026)
- Sector / Industry: Health Care / Medical Equipment & Supplies
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
